Vanda Pharmaceuticals rejects Future Pak’s acquisition offer
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ranging from $7.25 to $7.75 per share in cash, coupled with certain Contingent Value Rights (CVRs), was unanimously rejected by Vanda’s Board of Directors after thorough consultations with independent financial […]